Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TheraBreath Dry Mouth Lozenges are an over-the-counter oral care product designed to alleviate symptoms of xerostomia (dry mouth). Formulated by Dr. Harold Katz, the lozenges utilize a blend of ingredients including xylitol, zinc gluconate, and *Spilanthes acmella* flower extract. The mechanism of action involves a three-stage process: refreshing the mouth with flavor, stimulating natural saliva production via sialogogue properties, and providing immediate moisture to the oral cavity. They are commonly used by individuals experiencing dry mouth as a side effect of medications (such as antidepressants) or due to medical conditions like Sjögren's Syndrome. The product is marketed as a non-pharmaceutical oral care aid and is certified vegan, gluten-free, kosher, and diabetic-friendly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TheraBreath Dry Mouth Lozenges.